Cadila announced that the board of directors of the company at a meeting held on April 30, 2020, have signed an agreement for the sale of the shares that it holds of Windlas Healthcare Private Limited (WHPL).

After the rapid spread of Coronavirus, the gold prices were seen zooming as this safe-haven asset was preferred during the time when the economies globally were busy implementing lockdowns.

Crude oil prices have seen a jump lately, as number of signs indicated that US crude glut is increasing at a comparatively lower rate than what was expected earlier thereby, sending an emotion of relief globally.

For the benchmark indices, the current week was full of gaining sessions as even today i.e. on April 30, Sensex rose by 997.46 points which is 3.05 per cent higher than its previous close to reach the level of 33,717.62 while, Nifty jumped by 306.55 points, which is 3.21 per cent to be at the level of 9,859.90.

Nutanix, an enterprise cloud computing company, in association with Wipro Limited, announced the launch of Wipro’s digital database services (DDS) powered by Nutanix Era and Nutanix HCI software.

After the announcement of corporate tax cut in September last year, the markets have seen a gradual rise in monthly trading volumes. From 18.43 lakh shares, the average volume reached 24.6 lakh shares from September to February.

The stock of petroleum lubricating oil & grease manufacturing company, GP Petroleums Ltd (GPPL), jumped over seven per cent after the company announced that it has resumed operations at its 80,000 tonnes Vasai lubricant plant (Maharashtra).

The stock price has already seen a strong run-up in the recent times due to the buzz of the buyback, coupled with positive sentiments in the market. It has gained as much as 20 per cent within a span of just one week.

KEC International informed the bourses today that it has resumed operations/dispatches at all its five factories in India in a phased manner

Glenmark Pharmaceuticals, a research-led integrated global pharmaceutical company, announced that it has received an approval from Drug Controller General of India (DCGI) to conduct clinical trials on Favipiravir Antiviral tablets on COVID-19 patients.